INVESTORS
Market Opportunity
The pharmaceutical market has relied on the same analytical technology for the past 35-40 years. These processes are integral to every stage of a drug's life cycle, from early research and development in the discovery phase through clinical trials and process R&D to production.
The aging process is complex, requiring multiple scientists, five to six sophisticated instruments, over 40 consumables, and more than 24 hours for actionable data. Smaller pharma companies may take one to two weeks to outsource testing.
Novilytic has addressed this issue with its Proteometer consumable kits. This patented BioTool allows a scientist to gather essential data in just 10 minutes using one instrument and a single consumable. We are "Simplifying BioAnalysis."
Novilytic offers a substantial opportunity for investors. Big Pharma spends over $2 billion annually on consumables for analyzing protein-based drugs. Our patented technologies allow scientists to replace these with the easy-to-use Proteometer kit, enabling quick data collection using their own instruments.
Market and Commercialization Strategy
Our marketing strategy prioritizes the late Discovery, Clone Selection, and Process R&D steps in medicinal development, where we conduct millions of tests annually.
Our tactical efforts will highlight the Proteometer's new efficiencies and simplicity, emphasizing its “plug-and-play” design that integrates with existing tools and workflows.
The go-to-market strategy pairs business development specialists with technical product managers to meet market expectations and attract potential suitors. All manufacturing will take place at QMOS and ISO-validated suppliers, supporting our assembly strategy for strong profits and rapid market expansion.
Technical and Competitive Advantage
The Proteometer platform uses nanoparticles and small-molecule ligands to target specific protein components. We are addressing key market needs with three initial versions and plan to launch 2-3 new products in 2026, expanding into animal analytics, mNRA, DNA, and food-based protein markets.
Our patented nanotechnology is exclusive to us, and we’ve received approval from four of the top five global instrument companies for ease of use. Pilots at leading pharmaceutical companies have validated its effectiveness, resulting in published peer-reviewed articles showcasing how the Proteometer has streamlined their operations.
Artificial Intelligence Opportunities
The Proteometer provides critical data for our target market by integrating with existing instruments and using proprietary AI to deliver only the necessary information. This helps pharmaceutical scientists avoid the "garbage in, garbage out" issue. A major advantage is that companies can use their current software, enhanced with actionable data, without extensive training or security checks.
Regulatory Strategy and Intellectual Property
The Proteometer does not require FDA approval and is first being adopted in Pharmaceutical Discovery, Clone Selection, and Process R&D without regulatory restrictions. If used in manufacturing, it will be part of the FDA submittal. Since over 90% of our target users are outside manufacturing, regulatory approval is not central to our IP Go-to-Market strategy. Our IP includes various methods and patents that safeguard against duplication, with additional patents pending.